Vivoryon Therapeutics N.V.
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
19 oct 2015 - 08:06
Statutory name
Vivoryon Therapeutics N.V.
Title
Probiodrug presented data on its pGlu-3 Abeta monoclonal Antibody at Neuroscience 2015, Chicago
Comments
Probiodrug presented data on its pGlu-3 Abeta monoclonal Antibody
at Neuroscience 2015, Chicago
Presentation at the Society for Neuroscience (SfN) Annual Meeting
HALLE/SAALE, Germany, 19 October 2015 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), presented data on its specific pGlu3-Abeta monoclonal antibody at Neuroscience 2015, the 45th annual meeting of the Society for Neuroscience (SfN) in Chicago, USA.
The data presented result from a collaboration between Probiodrug and the research team led by Associate Professor Cynthia Lemere from the Center for Neurologic Diseases at the Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Related downloads
Date last update: 09 November 2025